Close Menu

Mount Sinai

Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.

Such tests indicate whether a person had an immune response to the virus, which could aid infection tracking and identifying individuals with immunity.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.

Neurosurgeon Christopher Kellner is developing a test for aneurysm detection and leading an industry-funded effort to profile blood clots from stroke patients.

The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.

The firm did not disclose the size of the funding, which is helping it build on its Centrellis Health Intelligence Platform and move to whole-exome sequencing. 

With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.

The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.

The spinout expects to launch its artificial intelligence- and biomarker-based monitoring tool in the third quarter of this year.

Pages